Results 151 to 160 of about 69,250 (228)

Safety of oil from Schizochytrium sp. A2 for use in infant and follow‐on formula as a novel food pursuant to regulation (EU) 2015/2283

EFSA Journal, Volume 24, Issue 5, May 2026.
Abstract Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on the safety of an oil derived from the microalga‐like organism Schizochytrium sp. A2 as a novel food (NF) pursuant to Regulation (EU) 2015/2283.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Dominique Turck, Torsten Bohn, Montaña Cámara, Jacqueline Castenmiller, Stefaan De Henauw, Ángeles Jos, Alexandre Maciuk, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Thomas Frenzel, Margarita Aguilera‐Gómez, Francesca Marcon, Monika Neuhäuser‐Berthold, Irene Nuin Garciarena, Emanuela Turla, Areti Favata, Karen Ildico Hirsch‐Ernst   +22 more
wiley   +1 more source

Unraveling the role of <i>TP53</i> mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation. [PDF]

Hemasphere
da Silva-Benedito S, Bernardo PS, Martin JE, Marty C, Plo I, Antony-Debré I, Monte-Mór BDCR.   +6 more
europepmc   +1 more source

Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97). [PDF]

Front Oncol
Felser S, Koeppel M, Kuehl R, le Coutre P, Al-Ali HK, Schulze S, Muegge LO, Bormann J, Geissler J, Dadgar A, Junghanss C, Ulbricht S.   +11 more
europepmc   +1 more source

Risk stratification of patients with TP53-mutated myeloproliferative neoplasms. [PDF]

Leukemia
Rolles B, Filho CMO, Fergusson N, Bewersdorf JP, Keating J, Perkins C, Schwede M, England J, Luskin MR, DeAngelo DJ, Shimony S, Faiz M, Hillerbrand AC, Kim C, Weeks LD, Waldman L, Wazir M, How J, Marneth AE, Liu Y, Aryee MJ, Rampal R, Tsai HK, Gotlib J, Gupta V, Stahl M, Mullally A.   +26 more
europepmc   +1 more source

Role of Chitinase 3-like-1 in Myelofibrosis via Fibroblast-Produced Extracellular Matrix Enhancement. [PDF]

J Cell Physiol
Kato S, Kawamura T, Maekawa T, Ogata H, Tachi N, Osawa Y, Kobayashi S.   +6 more
europepmc   +1 more source

Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. [PDF]

Blood Adv
Leiva O, Soo S, Liu OC, You V, Palmer A, Kahla J, Murtaza Y, Odenike O, Patel AA, DeCara JM, Dubielecka PM, Petersen M, Lee MH, How J, Hobbs G.   +14 more
europepmc   +1 more source

Murray Inc. and International Union, United Automobile, Aerospace and Agricultural Implement Workers of America (UAW) Local 1621 (2002) [PDF]

, 2002

core   +1 more source

Immature Platelet Fraction as a Potential Biomarker of Dysregulated Thrombopoiesis in Philadelphia-Negative Myeloproliferative Neoplasms. [PDF]

J Clin Med
Zekanovic I, Marketin T, Moric Peric M, Zekanovic D, Vulic A, Milos M, Bogic A, Marcinkovic M, Grbic Pavlovic P, Radic Antolic M, Knezevic J, Jurlina L, Boban A.   +12 more
europepmc   +1 more source

Ruxolitinib treatment in patients with polycythemia vera reduces <i>JAK2</i> variant allele frequency and improves symptom burden and hematocrit control. [PDF]

Ther Adv Hematol
Harrison CN, Kiladjian JJ, Hamer-Maansson JE, Naim A, Palandri F, Passamonti F.   +5 more
europepmc   +1 more source